Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Corporate News
- Waterside Capital (WSCC) Reports a Quarterly Loss
- Ship Finance (SFL) Posts Q3 adj.-EPS of $0.47, Misses Estimates
- Frontline (FRO) Posts Q3 Loss of $0.07, Beats Street by 5c
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.
Teva originally filed suit against Momenta/Sandoz in August 2008 for infringement of multiple patents (seven in the Orange Book which extend through May 24, 2014), covering the chemical composition of COPAXONE, pharmaceutical compositions containing it and methods of using it. Teva seeks leave to amend its complaint to include the additional patents related to the characterization of the active ingredient in COPAXONE. These patents do not expire until several years after the patents currently in litigation.
COPAXONE is a highly-complicated product to develop and manufacture, and given the inability to fully characterize the active ingredients of COPAXONE, Teva has serious doubts about any generic applicant's ability to demonstrate conclusively that the composition of its product is identical to that of COPAXONE. Internal research at Teva has indicated that even minor changes in the synthetic process and/or molecular weight distribution of a glatiramoid (glatiramir acetate-like substance) can have severe ramifications on the safety and mechanism of action of the product.
Teva contends that any company that files an application for any glatiramoid, via an ANDA or 505(b)(2) application, should conduct pre-clinical testing as well as full-scale, placebo-controlled clinical trials with measured clinical endpoints in MS patients to establish safety, efficacy and immunogenicity in this patient population.
Related Categories
Corporate NewsStocks Mentioned
-0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
